66215-604 : Uptravi 400 ug/1 Oral Tablet, Coated


NDC: 66215-604
Labeler: Actelion Pharmaceuticals Us, Inc.
Product Type: Human Prescription Drug
Drug Name:  Uptravi
Dosage Form: Oral Tablet, Coated
Application #: NDA207947
Rev. Date: 


Appearance:


Markings: 4
Shapes:  Round
Colors:  Red
Size (mm): 7
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 66215-604-06: 1 BOTTLE IN 1 CARTON (66215‑604‑06) > 60 TABLET, COATED IN 1 BOTTLE

Active Ingredients:

  • Selexipag

Dosage Strength:

  • 400 ug/1

Pharmaceutical Classes:

  • Prostacyclin Receptor Agonist [EPC]
  • Prostacyclin Receptor Agonists [MoA]

Related Products:

Based on records with the same trade name.
  • 66215-602 Uptravi 200 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-606 Uptravi 600 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-608 Uptravi 800 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-610 Uptravi 1000 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-612 Uptravi 1200 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-614 Uptravi 1400 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-616 Uptravi 1600 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
  • 66215-718 Uptravi 1800 ug/10ml Intravenous Injection, Powder, for Solution by Actelion Pharmaceuticals Us, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 66215-604 QR Code

< Prev: 66215-602Next: 66215-606 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.